Back

Effects of linagliptin vs glimepiride stratified by prior insulin secretagogue use in the cardiovascular outcome study of linagliptin versus glimepiride in type 2 diabetes (CAROLINA) trial

31 August 2020 (08:30 - 08:30)
Organised by:
Congress Presentation Part of: Improving Cardiovascular Function and Clinical Outcome in Diabetes Using New Guideline-Based Pharmacotherapy Antidiabetic Pharmacotherapy ESC Premium Access ESC Congress 2020

About the speaker

Photo
Professor Darren Keith McGuire

University of Texas Southwestern Medical Center, Dallas (United States of America)

7 More presentations in this session

Presentation thumbnail
Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial.
Doctor G. Ferrannini (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Cardiovascular outcomes in patients with type 2 diabetes and reduced eGFR and albuminuria: a REWIND post hoc subgroup analysis
Professor H. Colhoun (Edinburgh, GB)
Abstract Slides Video
Presentation thumbnail
Direct effects of canagliflozin on human myocardial redox signalling: a novel role for SGLT1 inhibition
Doctor H. Kondo (Yufu City, JP)
Abstract Slides Video
Presentation thumbnail
Impact of polyvascular disease and renal dysfunction on cardiovascular outcomes in diabetes: post hoc analyses from EMPA-REG OUTCOME
Professor S. Verma (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
Natriuretic effect of 2 weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function: results of the DAPASALT trial
Professor H. Heerspink (Groningen, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Improving Cardiovascular Function and Clinical Outcome in Diabetes Using New Guideline-Based Pharmacotherapy

The Event

Event poster

ESC Congress 2020

31 August 2020 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Meta-analysis of cardiovascular outcome trials assessing the cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus
27 August 2021
thumbnail
Congress Presentation
Comparative effect of 3 different fix-combination antihypertensive treatments in fasting glucose, fasting insulin, OGTT and HbA1c levels, in prediabetic hypertensive patients
28 August 2022
thumbnail
Congress Presentation
Metformin is associated with lower risks of incident cancers compared to sulphonylurea use: a population-based study with competing risk analyses
31 August 2024
thumbnail
Congress Presentation
Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial
31 August 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources